Showing 3611-3620 of 7768 results for "".
- Telehealth Webinar from Cosmetic Surgery Forum Explores Best Practiceshttps://practicaldermatology.com/news/telehealth-webinar-available-from-cosmetic-surgery-forum/2460325/As dermatologists deal with the evolving COVID-19 crisis, they are increasingly searching for guidance on the proper use of telemedicine. Joel Schlessinger, MD, Founder of Cosmetic Surgery Forum, brought together George Hruza, MD, past president of the AAD, and Antoanella Calame, MD, founder of t
- AMA: New CPT Code to Report Novel Coronavirus Testhttps://practicaldermatology.com/news/ama-new-cpt-code-to-report-novel-coronavirus-test/2460307/The Current Procedural Terminology (CPT®)Editorial Panel has approved a new addition to the CPT code set to report testing for the virus that causes COVID-19. The American Medical Association (AMA) says the code will help streamline data-driven resource and allocation planning in t
- SU2C Calls for Increased Diversity in Cancer Trialshttps://practicaldermatology.com/news/su2c-calls-for-increased-diversity-in-cancer-trials/2460265/Stand Up to Cancer (SU2C) announced a new diversity initiative that aims to make sure current advances in diagnosing and treating cancers don’t leave anyone out. The lack of diverse participation in cancer clinical trials may be due to socio-economic, cultural, trust and
- Researchers Elucidate Why Some Beta Blockers May Trigger or Exacerbate Psoriasishttps://practicaldermatology.com/news/researchers-elucidate-why-some-beta-blockers-may-trigger-or-exacerbate-psoriasis/2460211/Beta-blockers can trigger or exacerbate psoriasis, and now scientists at the University of Bonn and Freie Universität Berlin may know why. It appears that beta-blockers can interfere with the breakdown of defective cell components. In return, the cells release messengers that trigger immune-
- Foamix Update: Nine Trials in Five Postershttps://practicaldermatology.com/news/foamix-update-nine-trials-in-five-posters/2460192/Results from nine clinical trials of Foamix Pharmaceutical investigational products will be presented in five posters at the 39th Annual Fall Clinical Dermatology Conferencein Las Vegas. Findings relate FMX101 for the treatment of moderate-to-severe acne and FMX103 for the treatment of moderate-t
- AAD: Half of Americans Aren't Protecting Themselves from the Sunhttps://practicaldermatology.com/news/aad-half-of-americans-arent-protecting-themselves-from-the-sun/2460018/Most Americans aren’t using sun protection as often as they should be —increasing their risk for skin cancer, including melanoma. In fact, just half of Americans always or almost always protect themselves from the sun when they’re outside, according to a new survey by
- Mandy Moore, Garnier Team Up for Beauty Product Recyclinghttps://practicaldermatology.com/news/mandy-moore-garnier-team-up-for-beauty-product-recycling/2457854/Nearly half of Americans don’t recycle their beauty and personal care products, which is why they account for a significant amount of landfill waste, and This Is Us star Mandy Moore, #GarnierGirl and brand ambassador, is teaming up with Garnier and DoSomething.org to kick off the seco
- FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Diseasehttps://practicaldermatology.com/news/fda-approves-bmss-opdivo-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease/2457941/The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce t
- Aclaris Initiates Pilot Clinical Trial of ATI-50002 Topical for Vitiligohttps://practicaldermatology.com/news/aclaris-initiates-pilot-clinical-trial-of-ati-50002-topical-for-vitiligo/2457947/Aclaris Therapeutics, Inc., has initiated a Phase 2 open-label clinical trial of ATI-50002, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-50002 Topical) and an investigational drug, for the potential treatment of non-segmental vitiligo of the face. This trial will evaluate the safety, t
- Harnessing the Power of Social Media: One Viral Post Can Generate Tons of Skin Cancer Awarenesshttps://practicaldermatology.com/news/harnessing-the-power-of-social-media-one-viral-post-can-generate-tons-of-skin-cancer-awareness/2457953/You don’t have to be a celebrity to give voice to a public health concern on social media. Just one person can generate awareness about skin cancer -- when his or her post and picture is shared thousands of times on Facebook, researchers report in the journal Preventive Medicine